Recently FDA-approved treatments work to clear clumps of the protein amyloid beta in the brain. A drug that instead goes ...

A human biologist told Newsweek that Alzheimer's research should stop focusing on one molecule and study the wider system.

Alzheimer's sleep loss stems from overactive microglia, not amyloid plaques, a University of Kentucky study in Alzheimer's & ...

Researchers have uncovered a surprising culprit behind sleep loss in Alzheimer’s disease: the brain’s own immune cells. In ...

An analysis of the brain of a deceased Alzheimer's disease (AD) clinical trial participant found that regions where an ...

Eli Lilly’s anti-amyloid Alzheimer’s drug is designed to be stopped after patients drop below a certain amyloid level in the ...

Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid plaques and delays cognitive decline. Researchers from VIB and KU Leuven have ...

Add Yahoo as a preferred source to see more of our stories on Google. Astrocytes (green) attacking amyloid plaques (blue). (Yun Chen/Washington University) A new kind of cellular immunotherapy shows ...

Excessive activity of the brain's immune cells may play a key role in sleep disorders in Alzheimer's disease. In an experiment on mice, the temporary removal of most of these cells restored more than ...

Researchers at Baylor College of Medicine have discovered a natural mechanism that clears existing amyloid plaques in the brains of mouse models of Alzheimer's disease and preserves cognitive function ...